Comparing to previous quarter (Q4 is always Seasonally strong and Q1 is always weak), Axiron dropped 17%, but Androgel dropped sharp 40%.
With both main products are facing competition from generic drugs, it seems Axiron may maintain or even increases the market share but Androgel lost a lots.
The figure will show Axiron' market share likely above 14% at the worst.
$39.1m is not a rally, but further convinced sales stabilizing and FDA' impact is fading.
Add to My Watchlist
What is My Watchlist?
